コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 s when docetaxel + trastuzumab was used as a systemic therapy.
2 safely undergo surveillance before starting systemic therapy.
3 phy was predominantly the result of improved systemic therapy.
4 ssive mCRPC immediately prior to new line of systemic therapy.
5 e fluocinolone acetonide implant or standard systemic therapy.
6 outcome in patients with advanced HCC before systemic therapy.
7 influence the timing of surgery relative to systemic therapy.
8 itivity within weeks following initiation of systemic therapy.
9 f strategy A over strategy C was the cost of systemic therapy.
10 fore and after the completion of neoadjuvant systemic therapy.
11 lay (sometimes indefinitely) the delivery of systemic therapy.
12 uable disease, who had not received previous systemic therapy.
13 rmatory diagnostic testing before initiating systemic therapy.
14 er during or at the completion of first-line systemic therapy.
15 search was restricted to articles evaluating systemic therapy.
16 long plasma circulation, which is useful for systemic therapy.
17 proliferating infantile hemangioma requiring systemic therapy.
18 cancer with progression on hormonal and one systemic therapy.
19 after discontinuation of the drug and use of systemic therapy.
20 go complete resection after combined HAI and systemic therapy.
21 s been referred for consideration of further systemic therapy.
22 e NSCLC tumors that had been resected before systemic therapy.
23 months (mean, 131 months) after cessation of systemic therapy.
24 from the operation and proceeded to further systemic therapy.
25 ed acute GVHD were eligible if they required systemic therapy.
26 hepatocellular carcinoma (HCC) without prior systemic therapy.
27 tatic cancer as a consolidative partner with systemic therapy.
28 o undergo lumpectomy, radiotherapy (RT), and systemic therapy.
29 iasis who are candidates for phototherapy or systemic therapy.
30 nced in patients with suboptimal response to systemic therapy.
31 fore and after the completion of neoadjuvant systemic therapy.
32 l sanctuaries in the context of conventional systemic therapy.
33 irst 2 years compared with those assigned to systemic therapy.
34 atients (62%) were initially treated without systemic therapy.
35 metastatic breast cancer who were receiving systemic therapy.
36 were observed in 15 patients, all receiving systemic therapy.
37 patients could be initially managed without systemic therapy.
38 ecur and target this population for adjuvant systemic therapy.
39 ed with regional therapy and avoid delays in systemic therapy.
40 DLS/DDLS who had progressive disease despite systemic therapy.
41 nts were randomized to either FA implants or systemic therapy.
42 tinum compounds represent the cornerstone of systemic therapy.
43 1969-2003) and after (2004-2014) advances in systemic therapy.
44 th cGVHD after failure of 1 or more lines of systemic therapy.
45 s when docetaxel + trastuzumab was used as a systemic therapy.
46 mphocytic leukaemia (CLL) who do not require systemic therapy.
47 well owing to the widespread use of adjuvant systemic therapy.
48 hs occurred after 15 years in the absence of systemic therapy.
49 f strategy A over strategy C was the cost of systemic therapy.
50 orubicin administration method, and previous systemic therapy.
51 A) to guide decisions on the use of adjuvant systemic therapy.
52 patients who had undergone previous local or systemic therapy.
53 were conducted in patients who also received systemic therapy.
54 ancer who are deemed candidates for adjuvant systemic therapy.
55 ntial whole-breast irradiation, and adjuvant systemic therapy.
56 n who did not receive the indicated adjuvant systemic therapy.
57 r guiding decisions on the need for adjuvant systemic therapy.
58 with breast-conserving therapy and adjuvant systemic therapy.
59 ration can decrease the benefit of cytotoxic systemic therapies.
60 vival, particularly in patients treated with systemic therapies.
61 ts were enrolled, with a median of two prior systemic therapies.
62 dertaken, with 198 MF/SS patients undergoing systemic therapies.
63 o GVHD treatment, and 14 of 17 required >/=2 systemic therapies.
64 All patients had received multiple previous systemic therapies.
65 Incidence of HZ associated with systemic therapies.
66 treatment regimens, including a median of 4 systemic therapies.
67 meet the criteria of surrogacy with specific systemic therapies.
68 gnosis and in helping to assess responses to systemic therapies.
69 onsible for the poor response of patients to systemic therapies.
70 uncover biomarkers predictive of response to systemic therapies.
71 ct, on the basis of incidence and benefit of systemic therapies.
72 between the 2 treatment groups (implant vs. systemic therapy, 2 letters; 95% CI, -10 to 15 letters;
73 teen patients were using a self-administered systemic therapy; 22.4% were classified as "non-adherent
74 visual acuity from baseline (implant, 61.7; systemic therapy, 65.0) through 7 years (implant, 55.8;
75 erapy, 65.0) through 7 years (implant, 55.8; systemic therapy, 66.2) favored systemic therapy by 7.2
76 uveitic eyes (71% of 90 patients assigned to systemic therapy) (77% female; median age at enrollment,
77 rized and considered in terms of customizing systemic therapy according to biomarker (ERCC1 and RRM1)
78 reviously developed to assess the quality of systemic therapy across four domains (access, treatment
79 implants were not significantly better than systemic therapy (adjusted HR for progression, 0.5; P =
81 is interest in the use of AC, the benefit of systemic therapy after neoadjuvant chemoradiation and es
82 assigned (1:1) to receive standard adjuvant systemic therapy alone (control group) or with zoledroni
83 wed by adjuvant systemic therapy relative to systemic therapy alone for patients with breast cancer l
84 ndomly assigned to receive standard adjuvant systemic therapy alone or with zoledronate administered
87 oved to be cost-effective when compared with systemic therapy alone, particularly in estrogen recepto
88 oved to be cost-effective when compared with systemic therapy alone, particularly in estrogen recepto
91 metastatic disease lesions after first-line systemic therapy, an Eastern Cooperative Oncology Group
92 ymal stromal cell therapy as alternatives to systemic therapies and antibiotics for patients with inf
94 the brain, which complicates decisions about systemic therapy and assessments of survivorship outcome
95 e base covered questions related to adjuvant systemic therapy and included a systematic review conduc
96 led, all with liver metastases refractory to systemic therapy and ineligible for surgical resection.
97 ravitreous fluocinolone acetonide implant vs systemic therapy and long-term visual and other outcomes
98 in BSRC, which underscore the importance of systemic therapy and offer new insights into the potenti
100 portantly, therapeutic advances in multidrug systemic therapy and radiation therapy have already been
102 luding the lack of suitable targets for safe systemic therapy and the need to achieve effective T cel
104 orbidity, the introduction of new, effective systemic therapies, and the improvement in survival time
106 2 or less, had received standard first-line systemic therapy, and had no disease progression before
107 s after brain radiotherapy and HER2-targeted systemic therapy are a difficult therapeutic challenge.
110 essed (P < 0.016), although most eyes in the systemic therapy arm also showed substantial improvement
111 ients with autoimmune diseases that required systemic therapy at screening were excluded from the stu
113 a patient is not a candidate for surgery or systemic therapy because of severe comorbid conditions,
114 by assigned treatment (129 implants vs. 126 systemic therapies) because of substantial differences i
117 to Alliance for Clinical Trials in Oncology systemic therapy breast cancer trials during 1985-2012 a
118 ups held strong beliefs about their need for systemic therapy but differed in levels of medication co
120 oved to be a preferable adjunct agent to the systemic therapy by preventing both the local and system
122 ease following one or more previous lines of systemic therapy consisting of at least two cycles of a
123 and also negatively affects the delivery of systemic therapy, contributes to morbidity of cancer tre
124 ere treated with 1 or more of the following: systemic therapy (corticosteroids or other immunosuppres
125 ed FU plus LV with a potentially more active systemic therapy could further improve overall survival.
126 acting OS, whereas discrepancies in adjuvant systemic therapies did not impact LR, DM, or OS of leiom
128 linicians when choosing between non-biologic systemic therapies, etanercept, adalimumab, and ustekinu
129 ing ocular melanoma), and up to one previous systemic therapy (excluding anti-CTLA-4, PD-1, or PD-L1
131 postoperative radiotherapy with and without systemic therapy following primary surgery of OPSCC, ind
132 estimate the relative efficacy and safety of systemic therapies for advanced, treatment-naive, BRAF-m
142 osine kinase inhibitor, is the only approved systemic therapy for advanced hepatocellular carcinoma (
143 Phase III randomized controlled trials of systemic therapy for advanced NSCLC between 1980 and 201
146 Randomized clinical trials of neoadjuvant systemic therapy for breast cancer may help resolve this
147 ay reduce the efficacy of molecularly guided systemic therapy for cancers that have metastasized.
148 was reasonably cost-effective compared with systemic therapy for individuals with unilateral interme
149 gical margins) who had not received previous systemic therapy for melanoma from 91 hospitals located
150 es represent the first major breakthrough in systemic therapy for melanoma leveraging the new genetic
151 In this largest prospective trial to date of systemic therapy for metastatic ASPS, we observed that c
153 continued on observation until initiation of systemic therapy for metastatic renal-cell carcinoma; a
154 lacebo in patients who had received no prior systemic therapy for metastatic soft tissue sarcoma.
155 ndations updating the 2015 ASCO guideline on systemic therapy for patients with stage IV non-small-ce
159 set priorities for improving the quality of systemic therapy for women with early-stage breast cance
160 l therapy and matched controls not receiving systemic therapy from April 11, 2011, through June 30, 2
164 mulative 7-year incidence in the implant and systemic therapy groups, respectively, was less than 10%
165 , or panuveitis, those randomized to receive systemic therapy had better visual acuity than those ran
166 About 90% of patients with NOPR-planned systemic therapy had evaluation or management claims fro
167 ive chemoprevention strategies, and only one systemic therapy has been approved for patients with adv
171 ous cell carcinoma is a deadly disease where systemic therapy has relied upon empiric chemotherapy de
172 ted therapy against AXL, in combination with systemic therapies, has the potential to improve respons
173 coma, a disease in which currently available systemic therapies have proven inefficacious, with an em
174 es in locoregional therapies, radiation, and systemic therapies have provided better therapeutic opti
176 BSRC patients with active disease naive to systemic therapy have elevated serum levels of 3 key imm
178 irst-line treatment, followed or replaced by systemic therapy if local therapy fails or cannot be per
181 om NSCLC that did not progress after initial systemic therapy improved progression-free survival comp
182 parison with a cohort receiving non-biologic systemic therapies in a propensity score-weighted Cox pr
185 entified all randomised controlled trials of systemic therapies in non-small-cell lung cancer, breast
187 andomized clinical trials (RCTs) of adjuvant systemic therapy in breast cancer make them impractical
188 We did a trial of dacomitinib as initial systemic therapy in clinically and molecularly selected
190 e-mode plans were much more often confirmed: systemic therapy in more than 85% of patients with ovari
191 maPrint assay to guide decisions on adjuvant systemic therapy in patients with hormone receptor-posit
192 Previous prognostic models for second-line systemic therapy in patients with metastatic renal cell
193 ed to characterise the time to initiation of systemic therapy in patients with metastatic renal-cell
195 pports the existence of impairment following systemic therapy in selected cognitive domains among som
196 enefit of hepatic radioembolization added to systemic therapy in the first- and second-line treatment
199 nation, and volume regimens with and without systemic therapy in the treatment of OPSCC are outlined
201 In contrast, potential complications of systemic therapy, including measures of hypertension, hy
204 The pipeline of more targeted topical and systemic therapies is expanding based on our growing und
205 r metabolic activity after the initiation of systemic therapy is an indicator of active disease, wher
206 recurrent malignancy at 1 year after initial systemic therapy is associated with clinical benefit, a
207 d during transfection) have been used when a systemic therapy is indicated for large tumour burden an
208 d over the last decade, but the selection of systemic therapy is not based on the anatomic origin of
209 ve, especially for unilateral cases and when systemic therapy is not feasible or is not successful.
211 l suggesting that exploration of neoadjuvant systemic therapy is worthy of further investigation in r
213 ffectiveness and side-effect considerations, systemic therapy may be indicated as the initial treatme
216 estrogen-receptor status, type and timing of systemic therapy, menopausal status, statin use, and tre
217 estrogen receptor status, type and timing of systemic therapy, menopausal status, statin use, and tre
221 assessment of tumor response to neoadjuvant systemic therapy (NST) in patients with breast cancer an
222 od-based biomarkers, functional imaging, and systemic therapy of advanced NETs and discuss results of
223 ublished clinical trials and case reports on systemic therapy of pediatric and adult patients with AD
224 terminated the pregnancy to allow immediate systemic therapy; of the remaining 36 women, 24 received
226 of successful randomized trials provides new systemic therapy options for patients with metastatic so
227 % CI = 0.60-1.41) compared with non-biologic systemic therapies or methotrexate-only (etanercept: HR
228 with severe psoriasis (defined as requiring systemic therapy or hospital admission): the risk ratio
229 were not treated with TNF inhibitors, other systemic therapies, or phototherapy (topical cohort).
230 value particularly in patients treated with systemic therapy (P < 0.01), whereas the prognostic valu
232 idisciplinary, involving surgery, radiation, systemic therapies, pathology, radiology, and other spec
236 paid by 60 d confirmed the NOPR plan of any systemic therapy, radiotherapy, or surgery in 79.3%, 64.
240 ness of liver resection followed by adjuvant systemic therapy relative to systemic therapy alone for
241 Participants who received only biologic systemic therapy reported improvement in physical health
242 n which events include grade 3-4 acute GVHD, systemic therapy-requiring chronic GVHD, relapse, or dea
243 reatic cancer is extremely poor, and current systemic therapies result in only marginal survival rate
244 ommendations for confirmatory testing before systemic therapy should be reconsidered and replaced wit
247 e of the toxicity and non-curative nature of systemic therapy, some of these patients could benefit f
248 re elevated among patients with PsO (without systemic therapy [ST] 1.37; with ST 1.97), PsA (without
249 ction followed by postoperative conventional systemic therapy (strategy A) versus conventional therap
250 ction followed by postoperative conventional systemic therapy (strategy A) versus conventional therap
252 ay serve as a pharmacodynamic assessment for systemic therapy such as dasatinib, a potent SRC kinase
253 atment included a combination of topical and systemic therapies, such as corticosteroids, dapsone, is
254 isk of glaucoma and cataract with respect to systemic therapy, suggesting that careful monitoring and
256 to 1 or 2 sentinel nodes, the radiation and systemic therapy that are part of modern multimodality b
257 on in LMS is surgery and despite progress in systemic therapy the outcome of patients with advanced/m
258 e, which sets the stage for consideration of systemic therapies to facilitate improved cell function
259 ndations Recommendations for the addition of systemic therapy to definitive radiotherapy in the treat
260 a manner that prioritizes early exposure to systemic therapy to maximize the treatment of micrometas
261 -cell carcinoma who had received no previous systemic therapy to receive pembrolizumab (anti-PD-1) at
262 For advanced HCC, sorafenib is the only systemic therapy to significantly prolong survival in pa
263 with breast-conserving surgery and adjuvant systemic therapy to undergo either whole-breast irradiat
264 influence surgical decisions and may affect systemic therapy trial eligibility, all young women with
265 for cancer patients 65 y or older receiving systemic therapy (use of 1 or more categories including
266 d non-adherence to conventional and biologic systemic therapies used for psoriasis and evaluated psyc
267 clude locoregional therapies, radiation, and systemic therapy used alone or in combination with other
268 ortion of eyes with macular edema improving (systemic therapy vs. implant, 65% vs. 77%; P=0.20) and r
269 left atrial appendage closure (LAAC) versus systemic therapy (warfarin) for prevention of stroke, sy
271 om registration on study until initiation of systemic therapy was 14.9 months (95% CI 10.6-25.0).
274 l benefit of radical therapies compared with systemic therapy was even more pronounced (5-year surviv
276 treated patients (62% with two to five prior systemic therapies) was 16.8 months, and 1- and 2-year s
277 in all patients (71% with two to five prior systemic therapies) was 22.4 months; 1-, 2-, and 3-year
278 omatic patients with CLL who did not require systemic therapy were enrolled at MD Anderson Cancer Cen
280 tive breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in Sou
282 were intolerant to at least one conventional systemic therapy, were enrolled from 122 investigational
283 d with strategy B when letrozole was used as systemic therapy, whereas it was only 0.3 QALMs when doc
284 d with strategy B when letrozole was used as systemic therapy, whereas it was only 0.3 QALMs when doc
285 C, following a prolonged period of induction systemic therapy, will be an area of intense scrutiny.
288 ng in mind the potential risk of resistance, systemic therapy with antibiotics should be exclusively
290 gy procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or
292 with stereotactic radiosurgery, and he began systemic therapy with ipilimumab on a clinical trial.
293 n patients with metastatic cancer undergoing systemic therapy with MEK inhibitors enrolled in clinica
294 ed comparative effectiveness trial comparing systemic therapy with oral corticosteroids and immunosup
295 an ultimately self-curing disease for which systemic therapy with pentavalent antimony (Sb) is effec
296 ments, including sentinel lymph node biopsy, systemic therapy with taxanes, platinum agents, or dose-
297 d progressed after no more than one previous systemic therapy, with an Eastern Cooperative Oncology G
298 randomized clinical trial of tamoxifen vs no systemic therapy, with more than 20-year follow-up.
299 ans for treatment (surgery, radiotherapy, or systemic therapy) within 90 d for lung and 180 d for pro
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。